Scarica l'app Stockscreener
111.53
3.12%
-3.885
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché A Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$115.42
Aprire:
$113.51
Volume 24 ore:
897.56K
Relative Volume:
0.41
Capitalizzazione di mercato:
$31.53B
Reddito:
$7.07B
Utile/perdita netta:
$1.29B
Rapporto P/E:
24.59
EPS:
4.5355
Flusso di cassa netto:
$993.00M
1 W Prestazione:
-5.32%
1M Prestazione:
-10.46%
6M Prestazione:
-9.26%
1 anno Prestazione:
-6.70%
Intervallo 1D:
$110.89
$114.19
Intervallo di 1 settimana:
$110.89
$117.03
Portata 52W:
$96.43
$160.27
Agilent Technologies Inc Stock (A) Company Profile
Nome
Agilent Technologies Inc
Settore
Industria
Telefono
(408) 345-8886
Indirizzo
5301 STEVENS CREEK BLVD, SANTA CLARA, CA
Compare A vs TMO, DHR, IDXX, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
A
Agilent Technologies Inc
|
111.57 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
TMO
Thermo Fisher Scientific Inc
|
477.06 | 184.15B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
188.05 | 137.93B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
575.49 | 47.82B | 4.30B | 1.06B | 1.04B | 13.08 |
|
WAT
Waters Corp
|
287.50 | 29.19B | 3.17B | 642.63M | 516.49M | 10.77 |
Agilent Technologies Inc Stock (A) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-20 | Iniziato | HSBC Securities | Buy |
| 2026-01-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-12-15 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-02 | Iniziato | Morgan Stanley | Overweight |
| 2025-10-08 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-08 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-10 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-04-05 | Aggiornamento | Stifel | Hold → Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-17 | Downgrade | UBS | Buy → Neutral |
| 2023-09-28 | Iniziato | Bernstein | Mkt Perform |
| 2023-07-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-05-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | Citigroup | Neutral |
| 2023-05-24 | Reiterato | Credit Suisse | Outperform |
| 2023-05-24 | Reiterato | Evercore ISI | Outperform |
| 2023-05-24 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-24 | Reiterato | Robert W. Baird | Outperform |
| 2023-05-24 | Reiterato | SVB Securities | Outperform |
| 2023-05-24 | Reiterato | Stifel | Hold |
| 2023-05-24 | Reiterato | TD Cowen | Outperform |
| 2023-05-24 | Reiterato | Wells Fargo | Overweight |
| 2023-05-11 | Iniziato | Barclays | Equal Weight |
| 2023-01-10 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-07-20 | Iniziato | UBS | Buy |
| 2022-07-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-02-23 | Reiterato | BofA Securities | Buy |
| 2022-02-23 | Reiterato | Citigroup | Buy |
| 2022-02-23 | Reiterato | Cowen | Outperform |
| 2022-02-23 | Reiterato | Evercore ISI | Outperform |
| 2022-02-23 | Reiterato | Stifel | Hold |
| 2022-02-23 | Reiterato | Wells Fargo | Overweight |
| 2021-11-23 | Reiterato | BofA Securities | Buy |
| 2021-11-23 | Reiterato | Cowen | Outperform |
| 2021-11-23 | Reiterato | Stifel | Hold |
| 2021-03-18 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-25 | Aggiornamento | UBS | Neutral → Buy |
| 2020-11-17 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-09-30 | Iniziato | Atlantic Equities | Neutral |
| 2020-08-19 | Reiterato | BofA Securities | Neutral |
| 2020-08-19 | Reiterato | Citigroup | Neutral |
| 2020-08-19 | Reiterato | Jefferies | Buy |
| 2020-08-19 | Reiterato | Robert W. Baird | Outperform |
| 2020-08-19 | Reiterato | SVB Leerink | Outperform |
| 2020-08-19 | Reiterato | Stifel | Hold |
| 2020-08-19 | Reiterato | Wells Fargo | Overweight |
| 2020-02-24 | Downgrade | Needham | Buy → Hold |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-11-26 | Reiterato | Needham | Buy |
| 2019-11-15 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | UBS | Buy → Neutral |
| 2019-07-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-15 | Downgrade | Barclays | Overweight → Equal Weight |
Mostra tutto
Agilent Technologies Inc Borsa (A) Ultime notizie
Vestcor Inc Sells 10,204 Shares of Agilent Technologies, Inc. $A - MarketBeat
Mackenzie Financial Corp Buys 324,461 Shares of Agilent Technologies, Inc. $A - MarketBeat
Legal & General Group Plc Raises Position in Agilent Technologies, Inc. $A - MarketBeat
Korea Investment CORP Has $12.95 Million Stake in Agilent Technologies, Inc. $A - MarketBeat
Blair William & Co. IL Decreases Holdings in Agilent Technologies, Inc. $A - MarketBeat
Lab chromatographs are quietly getting an AI upgrade in the US - AD HOC NEWS
Agilent Launches Advanced Therapeutics CDMO Solution for US and Canada - Contract Pharma
Agilent’s Biocare Deal Reshapes Pathology Presence As Shares Lag Targets - simplywall.st
Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States - BioSpace
Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More - AOL.com
Agilent launches unified CDMO business combining US, Canada units - Investing.com
Agilent Technologies, Inc. $A Shares Sold by Swiss National Bank - MarketBeat
Agilent launches unified CDMO division across Canada and United States - StreetInsider
Lab Chromatographs Are Quietly Getting Smarter. Here Is Why It Matters - AD HOC NEWS
Jim Cramer on Agilent Technologies: “I Don’t Think You Need It” - Yahoo Finance
Agilent Technologies, Inc. $A Shares Sold by Russell Investments Group Ltd. - MarketBeat
Agilent Bets On Pathology Innovation With Biocare Acquisition - Yahoo Finance UK
Agilent snaps up pathology firm Biocare Medical for $950 million - malaysiasun.com
Is Agilent Technologies Stock Underperforming the S&P 500? - inkl
Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy - CHEManager
Van ECK Associates Corp Sells 10,815 Shares of Agilent Technologies, Inc. $A - MarketBeat
Ceredex Value Advisors LLC Makes New $24.39 Million Investment in Agilent Technologies, Inc. $A - MarketBeat
Why Agilent Technologies Just Paid $950 Million For Biocare Medical (NYSE:A) - Seeking Alpha
First Trust Advisors LP Increases Stock Position in Agilent Technologies, Inc. $A - MarketBeat
Molecular Diagnostics Market Outlook: Set to Grow at 10%+ CAGR Through 2031 as Precision Medicine and Genetic Testing Advance, Says Mordor Intelligence - GlobeNewswire Inc.
Bank of America Maintains Neutral on Agilent Technologies (A) March 2026 - Meyka
Agilent to buy Biocare Medical from Excellere and GHO Capital - pehub.com
Agilent Technologies: $950 Million Acquisition Of Pathology Diagnostics Company Biocare Medical - Pulse 2.0
Agilent Technologies to acquire Biocare Medical for $950 million - The American Bazaar
Agilent Technologies to Acquire Biocare Medical in $950 Million Deal - Clinical Lab Products
Agilent to Acquire Biocare Medical in $950 Million All-Cash Deal - TradingView
Sullivan & Cromwell Advises Agilent On $950M Biocare Buy - Law360
Agilent to buy Biocare Medical for $950M - Healthcare Dive
Agilent Technologies to acquire Biocare Medical in $950m deal - Medical Device Network
Agilent buys Biocare for $950M - BioWorld MedTech
BofA reiterates Agilent stock rating on Biocare acquisition - Investing.com
Agilent stock rises on $950M Biocare Medical acquisition - Investing.com South Africa
Agilent expands pathology portfolio with acquisition of Biocare Medical for $950 M - BioSpectrum India
Agilent to acquire Biocare Medical in $950 million all-cash deal - PharmaLive
Sienna Gestion Sells 26,245 Shares of Agilent Technologies, Inc. $A - MarketBeat
Victory Capital Management Inc. Boosts Stake in Agilent Technologies, Inc. $A - MarketBeat
Hims & Hers shares soar premarket; Pfizer, Agilent Technologies slip - Investing.com
Agilent to acquire Biocare Medical for $950M, expanding pathology portfolio - MSN
Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions - BioSpace
M&A News: Agilent to Buy Biocare Medical for $950M — What Investors Should Know - TipRanks
Agilent Technologies, Inc. (NYSE:A) entered into a definitive agreement to acquire Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP for ap - marketscreener.com
Why Agilent Stock Is Slipping Premarket Today - Stocktwits
Excellere Partners and GHO Capital Sell Biocare Medical to Agilent Technologies - National Today
Agilent Technologies to Acquire Biocare Medical for $950 Million - marketscreener.com
Agilent to buy Biocare Medical in $950 million all-cash deal - marketscreener.com
Agilent Buys Medical Instruments Maker Biocare for $950 Million - Bloomberg
Agilent Technologies Inc Azioni (A) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.33%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):